Trial Profile
A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Pfizer
- 04 Apr 2024 Planned End Date changed from 26 Mar 2025 to 22 Mar 2025.
- 04 Apr 2024 Planned End Date changed from 26 Mar 2025 to 22 Mar 2025.
- 04 Apr 2024 Planned primary completion date changed from 26 Mar 2025 to 22 Mar 2025.